CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
22-118

APPROVAL LETTER
NDA 22-118

B & H Consulting Services, Inc.
US Agent for LifeCycle Pharma A/S
Attention: Elizabeth Dupras, Project Manager
55 North Gaston Avenue
Somerville, NJ 08876

Dear Ms. Dupras:

Please refer to your new drug application (NDA) dated September 28, 2006, received
September 29, 2006, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and
Cosmetic Act for Fenofibrate Tablets, 40 mg, 120 mg.

We acknowledge receipt of your submissions dated October 5, December 4 and 22, 2006,
January 19, February 2 and 5, June 1 and 4, July 6, and August 10, 2007.

This new drug application provides for the use of Fenofibrate Tablets:

1. **Hyperlipidemia and Mixed Dyslipidemia**: as adjunctive therapy to diet to reduce
elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C in adult
patients with primary hyperlipidemia or mixed dyslipidemia. Lipid-altering agents should
be used in addition to a diet restricted in saturated fat and cholesterol when response to
diet and non-pharmacological interventions alone has been inadequate.

2. **Hypertriglyceridemia**: as adjunctive therapy to diet for treatment of adult patients with
hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting
chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia
thereby obviating the need for pharmacologic intervention.

We have completed our review of this application, as amended. It is approved, effective on the
date of this letter, for use as recommended in the submitted, agreed-upon labeling text and with
the minor editorial revisions listed below.

Revise the 7-count bottles to include the statement “Professional Sample-Not for Sale”.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, please submit the
content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described
at [http://www.fda.gov/oc/datacouncil/spl.html](http://www.fda.gov/oc/datacouncil/spl.html) that is identical to the submitted, enclosed labeling
(text for the package insert). Upon receipt, we will transmit that version to the National Library
of Medicine for public dissemination. For administrative purposes, please designate this
submission, “SPL for approved NDA 22-118.”
CARTON AND IMMEDIATE CONTAINER LABELS
Submit final printed container labels that are identical to those submitted September 28, 2006, except with the revision listed above, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005). Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “Final Printed Carton and Container Labels for approved NDA 22-118.” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

PROPRIETARY NAME
If you choose to use a proprietary name for this product, the name and its use in the labels must conform to the specifications under 21 CFR 201.10 and 201.15. We recommend that you submit any proprietary name to the Agency for our review prior to its implementation.

PEDIATRIC RESEARCH EQUITY ACT (PREA)
All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application.

PROMOTIONAL MATERIAL
You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see www.fda.gov/ceder/ddmac.
LETTERS TO HEALTH CARE PROFESSIONALS
If you issue a letter communicating important safety related information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
HFD-001, Suite 5100
5515 Security Lane
Rockville, MD 20852

REPORTING REQUIREMENTS
We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kati Johnson, Regulatory Project Manager, at (301) 796-1234.

Sincerely,

{See appended electronic signature page}

Mary H. Parks, MD
Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure: Package Insert